Pulmonx Corporation (LUNG) Stock Analysis & Investment Frameworks
Pulmonx Corporation (LUNG) stock analysis on Invetso. Review Pulmonx Corporation’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Pulmonx Corporation Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
Pulmonx Corporation Key Financial Metrics
- Market Cap: $109.95M
- Revenue: $90.50M
- ROE: -98.23%
- ROIC: -43.32%
- Dividend Yield: N/A
About Pulmonx Corporation
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
Pulmonx Corporation Investment Frameworks
Invetso analyzes Pulmonx Corporation (LUNG) across the following frameworks:
- Pulmonx Corporation 10Y Growth Potential
- Pulmonx Corporation Scenario Analysis
- Pulmonx Corporation Risks & Opportunities
- Pulmonx Corporation Economic Moat
- Pulmonx Corporation Business Model
- Pulmonx Corporation Management
- Pulmonx Corporation SWOT Analysis
- Pulmonx Corporation Porter's 5 Forces
- Pulmonx Corporation PESTLE Analysis
- Pulmonx Corporation ESG Analysis